Fda Division Of Medication Error Prevention And Analysis
Contents |
Home Food Drugs Medical Devices Radiation-Emitting Products Vaccines, Blood &
Medication Error Definition
Biologics Animal & Veterinary Cosmetics Tobacco Products About FDA Home About medication errors statistics FDA FDA Organization Office of Medical Products and Tobacco About the Center for Drug Evaluation and medication errors in nursing Research Office of Surveillance and Epidemiology (OSE) - Divisions Share Tweet Linkedin Pin it More sharing options Linkedin Pin it Email Print Office of Surveillance and
Types Of Medication Errors
Epidemiology (OSE) Home OSE Organization(PDF - 84KB) OSE Organization Text Version The Office of Surveillance and Epidemiology consists of Six divisions: Office of Pharmacovigilance and Epidemiology Division of Pharmacovigilance I Division of Pharmacovigilance II Division of Epidemiology I Division of Epidemiology II Office of Medication Error Prevention and Risk Management Division of
Medication Errors Statistics 2015
Medication Error Prevention and Analysis Division of Risk Management Office of Pharmacovigilance and Epidemiology (OPE) Division of Pharmacovigilance (DPV I & DPV II) Safety Evaluators and Medical Officers in DPV-I and DPV-II detect safety signals and assess safety-related issues for all marketed drug and therapeutic biologic products. They use a variety of surveillance tools including adverse event report data, published scientific literature, and preclinical, clinical, and pharmacologic knowledge of the products to provide scientific and clinical evaluation that leads to various regulatory actions and communications for safe use of the marketed products. Division of Epidemiology (DEPI I & DEPI II) Our epidemiologists conduct active drug safety surveillance using Sentinel’s ARIA system (Active Risk Identification and Analysis), and .review drug safety-related epidemiologic study protocols and study reports that are required of manufacturers as post marketing requirements (PMRs) and commitments. They serve as the Agency lead in ensuring that the PMRs conducted by sponsors meet the best pract
Home Food Drugs Medical Devices Radiation-Emitting Products Vaccines, Blood & Biologics Animal & preventing medication errors Veterinary Cosmetics Tobacco Products For Consumers Home For Consumers Consumer Updates
Examples Of Medication Errors
Avoiding Medication Mistakes Share Tweet Linkedin Pin it More sharing options Linkedin Pin it Email Print On medication error articles This Page: Examples of Medication Errors FDA's Role NOTE: Go to "6 Tips to Avoid Medication Mistakes" for more easy steps you can follow. A medication error is http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm169536.htm any preventable event that may cause or lead to inappropriate medication use or harm to a patient. Since 2000, the Food and Drug Administration (FDA) has received more than 95,000 reports of medication errors. FDA reviews reports that come to MedWatch, the agency's adverse event reporting program. "These reports are voluntary, so the number of http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm048644.htm actual medication errors is believed to be higher," says Carol Holquist, R.Ph., Director of the Division of Medication Error Prevention and Analysis in FDA's Center for Drug Evaluation and Research. FDA works with many partners to track medication errors, including the U.S. Pharmacopeia (USP) and the Institute for Safe Medication Practices (ISMP). "Every report received through the USP/ISMP Voluntary Medication Error Reporting Program (MERP) automatically gets sent to FDA's MedWatch program," says Mike Cohen, R.Ph., Sc.D., President of ISMP. "It takes a cooperative approach to monitor errors, evaluate them, and educate the public about strategies to keep errors from happening again." Medication errors occur for a variety of reasons. For example, miscommunication of drug orders can involve poor handwriting, confusion between drugs with similar names, poor packaging design, and confusion of metric or other dosing units. "Medication errors usually occur because of multiple, complex factors," says Holquist. "All parts of the health care system—including health professionals and patients—have a role to play in preventing medicatio
Home Food Drugs Medical Devices Radiation-Emitting Products Vaccines, http://www.fda.gov/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/ucm403376.htm Blood & Biologics Animal & Veterinary Cosmetics Tobacco Products Drugs Home Drugs Development & Approval Process (Drugs) CDER Small Business and Industry Assistance CDER Small Business and Industry Assistance (CDER SBIA) Webinar on “Overview of FDA’s Proprietary Name Review Process” - July 15, 2014 Share Tweet Linkedin Pin it More sharing medication error options Linkedin Pin it Email Print The Food and Drug Administration, Center for Drug Evaluation and Research Small Business and Industry Assistance (CDER SBIA) is pleased to inform you of a unique opportunity for small business entities to learn more about the FDA and basic drug regulation. Our webinar series of medication error highlights various aspects of drug regulation.These focused webinars support the CDER SBIA’s mission of promoting productive interaction with regulated industry by assisting small pharmaceutical business and industry with information relating to the development and regulation of human drug products.On Tuesday July 15, 2014, CDER Small Business and Industry Assistance (CDER SBIA) hosted a webinar entitled “Overview of FDA’s Proprietary Name Review Process.”FDA published a notice in the Federal Register announcing the availability of the draft Guidance for Industry - Best Practices in Developing Proprietary Names for Drugs.This webinarprovided an overview of the Proprietary Name Review guidance that focuses on the safety aspects in the development and selection of proposed proprietary names for all prescription and nonprescription drug products and biological products.The draft guidance provides a qualitative systematic framework for evaluating proprietary names before submitting them for FDA review.FDA is issuing this guidance to help sponsors of drug and biological p
be down. Please try the request again. Your cache administrator is webmaster. Generated Sat, 15 Oct 2016 18:01:39 GMT by s_wx1131 (squid/3.5.20)